Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | CLK1 | P49759 | 1/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | LATS1 | O95835 | 2/20 | 0.55 |
| ▸ | PDE5A | O76074 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 2/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16183678 | 0.94 | MEN1 (0.71) | MEN1KMT2ACLK1ABCG2LATS1 | |
| SCHEMBL16183674 | 0.94 | MEN1 (0.77) | MEN1KMT2ACLK1ABCG2LATS1 | |
| SCHEMBL16183679 | 0.90 | MEN1 (0.68) | MEN1KMT2ACLK1ABCG2LATS1 | |
| SCHEMBL14475181 | 0.90 | MEN1 (0.58) | MEN1KMT2ACLK1ABCG2LATS1 | |
| SCHEMBL16183676 | 0.89 | MEN1 (0.69) | MEN1KMT2ACLK1ABCG2LATS1 | |
| SCHEMBL16183677 | 0.89 | MEN1 (0.69) | MEN1KMT2ACLK1ABCG2LATS1 | |
| SCHEMBL16183700 | 0.89 | MEN1 (0.58) | MEN1KMT2ACLK1ABCG2PDE5A | |
| SCHEMBL16183673 | 0.87 | MEN1 (0.67) | MEN1KMT2ACLK1LATS1PDE5A | |
| SCHEMBL16183675 | 0.87 | MEN1 (0.63) | MEN1KMT2ACLK1ABCG2LATS1 | |
| SCHEMBL16183768 | 0.86 | MEN1 (0.60) | MEN1KMT2ACLK1ABCG2LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | MEN1 4814/4885KMT2A 800/4885CLK1 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.